FDA approves Bayer's Sunharbo to prevent recurrent strokes

The FDA has approved Sunharbo, Bayer's once-daily oral blood thinner, making it the world's first Factor XIa inhibitor approved anywhere. It targets a novel clotting protein to reduce recurrent stroke risk when taken with antiplatelet therapy. Approval follows positive global Phase 3 trial results and could benefit hundreds of thousands of Americans annually.